Not Tagged
Not Tagged
['myeloid']
research by dana-farber led to the development of chrs, a clinical tool to assess the risk of progression in patients with clonal hematopoiesis (ch), a common precursor to myeloid malignancies. lachelle weeks, md, phd, ( ), discusses the findings presented at #ash22. 
Dana-Farber Cancer Institute - a leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 | https://t.co/HvCwkLltic